MalignanciesImatinibRemissionAbnormalitiesDurable hematologicCCyRChronic myeloidPrognosisAbnormalityProgressionPredictsChromosomesTransfusionMolecular responsesBone marrow failureTyrosineIndicationSuboptimalAntitumorRatesPartialLeukemiaIncompleteMutationsDiseaseFailureInductionDisordersPonatinibDurationTreatment responsesPatients treatedAchieve a completeAnalysisRiskRateTherapyCellsEffects
Malignancies6
- Therefore, the current descriptive and cross-sectional study sought to determine the cytogenetic analysis of frequent hematological malignancies in Pakistan. (scielo.br)
- The Immunology and Hematology Section supports studies on the basic mechanisms of antitumor immune responses and hematologic malignancies. (cancer.gov)
- Dmins are rare in hematologic malignancies and are generally associated with a poor prognosis. (hindawi.com)
- The occurrence of dmin is relatively low in hematologic malignancies. (hindawi.com)
- Chimeric antigen receptor (CAR) T-cell therapy is an example of how immunotherapy is revolutionizing the treatment of hematologic malignancies with unprecedented response rates in patients with relapsed/refractory lymphoma, multiple myeloma, and acute lymphoblastic leukemia. (ajmc.com)
- Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies. (cdc.gov)
Imatinib17
- Patients treated with imatinib, dasatinib, and nilotinib have shown meaningful rates of hematologic and cytogenetic response. (wikipedia.org)
- In chronic phase patients receiving imatinib first-line, mutation analysis is recommended only in case of failure or suboptimal response according to the ELN criteria. (cml-foundation.org)
- In imatinib-resistant patients receiving an alternative TKI, mutation analysis is recommended in case of hematologic or cytogenetic failure as provisionally defined by the ELN. (cml-foundation.org)
- [ 4 ] A study by Gugliotta et al that examined the use of imatinib in patients aged 65 years or older found that the response to imatinib was not affected by age. (medscape.com)
- In the IRIS (International Randomized Study of Interferon and STI571) study, imatinib produced a higher rate of complete cytogenetic response (CCyR) and major cytogenetic response (MCyR) compared with interferon alpha and cytarabinenal. (medscape.com)
- In the DASISION (DASatinib versus Imatinib Study In treatment-Naive CML patients) trial, final 5-year analysis showed significantly higher MMR and molecular response with ≥4.5 log reduction of BCR-ABL on the International Scale (MR4.5) in patients with newly diagnosed CP-CML who received dasatinib, 100 mg once daily (n = 259), than in those who received imatinib, 400 mg once daily (n = 260). (medscape.com)
- Bosutinib has the potency to induce deep and fast responses in second- and third-/fourth-line treatment, and as a consequence, the drug has recently been licensed for patients previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib, and dasatinib are not considered appropriate treatment options. (mdm2-receptor.com)
- Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. (medscape.com)
- Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. (medscape.com)
- Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. (medscape.com)
- These enable patients to not only achieve MMR faster but also much deeper molecular responses than imatinib. (biomedcentral.com)
- Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. (medscape.org)
- Whilst nearly all CML sufferers taken care of with imatinib present major hematologic and cytogenetic responses, resistance to imatinib is obviously a barrier to effective therapy of CML patients. (screeninglibraries.com)
- Treatment is with tyrosine kinase inhibitors (TKI) such as imatinib , dasatinib , nilotinib , bosutinib , and ponatinib , which significantly improve response and prolong survival. (msdmanuals.com)
- Imatinib mesylate (Glivec ® /Gleevec ® ) is the standard first-line therapy for the treatment of chronic myeloid leukemia due to its high hematologic, cytogenetic, and molecular response rates and favorable long-term. (biomedcentral.com)
- Response to treatment is certainly measured with regards to hematologic cytogenetic and molecular variables as described in Desk 2 [2 13 Desk 2 Procedures of response in chronic myeloid leukemia and prognostic significance [2 13 Imatinib was initially approved in america in 2001 for the treating the advanced stages of CML. (healthcarecoremeasures.com)
- Our results confirm low response rate to imatinib in HES patients with unknown or negative PDGFRα status, and underscore the need for new therapeutic options for this disorder. (elsevierpure.com)
Remission4
- Hematological CR was accompanied by complete cytogenetic remission according to conventional cytogenetics in all evaluable cases. (biomedcentral.com)
- 2008 ). To further improve remission rates, time to response and response duration, combinations of AZA with other agents are being evaluated. (biomedcentral.com)
- It also explains key terms used in AML treatment such as complete remission, measurable residual disease (MRD), hematologic recovery, cytogenetic response, and molecular response. (youandaml.com)
- For patients with chronic myelomonocytic leukemia, the overall response rate was higher for azacitidine plus lenalidomide vs azacitidine alone (68% vs 28%, P = .02) but similar for all arms across cytogenetic subgroups, as was remission duration and overall survival. (ascopost.com)
Abnormalities4
- Suboptimal response was defined at 3 months (incomplete HR), 6 months (less than partial CgR), 12 months (less than complete CgR), 18 months (less than major molecular response [MMolR]), and, in case of MMolR loss, other mutations or other chromosomal abnormalities. (nih.gov)
- Thought to be disorders of hematopoietic stem cells, clonal cytogenetic abnormalities are frequently identified. (acgtfoundation.org)
- Criteria for diagnosis of MDS consist of anemia, thrombocytopenia, or neutropenia that persist for six months or longer, dysplasia greater than 10% in at least one bone marrow cell lineage, and MDS associated clonal cytogenetic abnormalities or molecular markers. (standardofcare.com)
- The cytogenetic abnormalities were described according to the International System for Human Cytogenetic Nomenclature (ISCN). (hindawi.com)
Durable hematologic1
- This case highlights the role of lenalidomide in modifying the course of low-risk del(5q) MDS in long-term responders by inducing a durable hematologic response and thereby contributing to control iron overload and improving long-term outcomes in selected patients. (deepdyve.com)
CCyR3
- Tasigna also showed a statistically significant improvement over Gleevec in every other measure of efficacy in the trial, including major molecular response (MMR) and complete cytogenetic response (CCyR) at 12 months(1). (salesandmarketingnetwork.com)
- Complete Hematologic Response (CHR) is when clinical presentations return to normal meanwhile, Complete Cytogenetic Response (CCyR) is when Ph is not detected. (biomedcentral.com)
- A molecular response is the major treatment endpoint with the optimal molecular response at BCR-ABL1 transcript level ≤ 10% by 3 months, ≤1% by 6 months is similar to CCyR and ≤ 0.1% by 12 months, known as Major Molecular Response (MMR). (biomedcentral.com)
Chronic myeloid1
- Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. (aboutscience.eu)
Prognosis1
- Lung cancer is the most common cause of cancer death worldwide, and its prognosis and treatment response rate as well as the survival rate remain poor. (deepdyve.com)
Abnormality2
- The defining cytogenetic abnormality, a translocation at the 8p11 locus, was found to involve the FGFR1 gene [ 14 ]. (nature.com)
- Routine G-banded karyotype, array-based comparative genomic hybridization, and fluorescence in situ hybridization analyses were used to characterize the cytogenetic abnormality in the patient's bone marrow. (hindawi.com)
Progression4
- In terms of the disease control rate (complete response + partial response + stable disease ratio), response rate (complete response + partial response ratio), median progression-free survival, and median time to progression, lenvatinib shows significantly better results compared with sorafenib, another oral multi-kinase inhibitor (75.5 vs. 60.5%, 24.1 vs. 9.2%, 7.4 vs. 3.7 months, 8.9 vs. 3.7 months, respectively) ( 7 ). (spandidos-publications.com)
- This branch administers extramural grants for studies in cancer genetics and epigenetics, including regulation of gene expression, mechanisms of DNA damage/repair, genomic instability, and related molecular, cytogenetic, and chromosomal effects during induction and progression to malignancy. (cancer.gov)
- The mechan isms of disorder progression and cytogenetic evolution to blast crisis remain unknown. (screeninglibraries.com)
- Aberrant activation of multiple intracellular signaling pathways has been exhibited in response to the presence of BCR-ABL resulting in accelerated cell cycle progression and inhibition of DNA repair which lead to abnormal maturation and genomic instability of hematopoietic stem cells [5]. (healthcarecoremeasures.com)
Predicts1
- A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. (cdc.gov)
Chromosomes1
- Double minute chromosomes (dmins) are cytogenetic indicators of extrachromosomal gene amplification which usually act as small spherical paired chromatin particles [ 1 ]. (hindawi.com)
Transfusion3
- Factors influencing response were AML (vs. MDS), marrow blast count, pretreatment, transfusion dependency, concomitant medication with hydroxyurea, and valproic acid (VPA) serum level. (biomedcentral.com)
- The primary endpoint was OS, and secondary endpoints included complete response, transfusion independence, and event-free survival. (medpagetoday.com)
- The advent of lenalidomide has fundamentally changed the treatment of patients with myelodysplastic syndrome (MDS) and deletion of the long arm of chromosome 5 (del(5q)), inducing high rates of red blood cell transfusion independence and cytogenetic response. (deepdyve.com)
Molecular responses3
- The down-regulation was consistent with decreased amounts of BCR-ABL1 in patients taking TKIs regardless of molecular responses. (biomedcentral.com)
- Therefore, these miRNAs have potential as new therapeutic biomarkers for BCR-ABL1 status in adult CML patients treated with TKIs at molecular responses. (biomedcentral.com)
- Treatment progress is measured based on hematologic, cytogenetic, and molecular responses. (biomedcentral.com)
Bone marrow failure1
- The myelodysplastic syndromes (MDS) are a group of clonal neoplastic hematologic disorders characterized by varying degrees of bone marrow failure, abnormal hematopoiesis, and proliferation of myeloid blast cells. (acgtfoundation.org)
Tyrosine1
- Here we propose comprehensive response criteria based on the heterogenous clinical presentations of patients with MLN with eosinophilia and tyrosine kinase gene fusions. (nature.com)
Indication2
- The effectiveness of Tasigna for this indication is based on confirmed hematologic and unconfirmed cytogenetic response rates. (salesandmarketingnetwork.com)
- Approval and indication are only based on response rates. (abcdocz.com)
Suboptimal2
- A dose increase of IM, alloHSCT, or investigational treatments were recommended in case of failure, and could be considered in case of suboptimal response. (nih.gov)
- Monitoring of response over the original a few months of therapy can be an integral element of the administration of sufferers with CML since it is essential to recognize people that have a suboptimal or insufficient response to preliminary treatment. (healthcarecoremeasures.com)
Antitumor1
- However, it is believed that direct antiproliferative action against tumor cells, inhibition of virus replication and modulation of the host immune response play important roles in antitumor and antiviral activity. (drugs.com)
Rates2
- The efficiency of this drug depends mostly on hematologic and cytogenetic response rates. (medexmd.com)
- 1 CAR T-cell therapy pivotal trials demonstrated unprecedented overall response rates (ORRs) and complete responses (CRs) that led to the FDA approval of 5 CAR T-cell products: tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), brexucabtagene autoleucel (brexu-cel), and idecabtagene vicleucel (ide-cel). (ajmc.com)
Partial1
- One patient with unknown PDGFRα status achieved complete hematologic response, and two (one PDGFRα negative and one status unknown) achieved partial hematologic response. (elsevierpure.com)
Leukemia1
- With a molecular/cytogenetic clonality marker, the disease is classified as chronic eosinophilic leukemia (CEL). (elsevierpure.com)
Incomplete2
- Complete response (CR, including incomplete hematologic recovery, CRi) occurred in 48% of the CPX-351 group versus 33% of patients who received conventional therapy. (medpagetoday.com)
- While effective, broad use of CAR T-cell therapies is limited by potential for life-threatening toxicities, challenges related to manufacturing a patient-specific product, high costs and inadequate reimbursement, and incomplete or unsustained disease response. (ajmc.com)
Mutations1
- Responses (with the combination) occurred rapidly, often within one cycle and were seen across all cytogenetic risk groups and molecular mutations," said Courtney DiNardo, MD, of the MD Anderson Cancer Center in Houston. (medpagetoday.com)
Disease3
- The majority of patients in each group had intermediate cytogenetic risk disease. (medscape.com)
- The EFS benefit and the overall survival benefit were consistent across subgroups, the researchers noted, including in patients with de novo disease, demographics, baseline cytogenetic risk status, World Health Organization AML classification, baseline white blood cell count, and baseline percentage of bone marrow blasts. (medscape.com)
- Lengthy time to response is problematic for patients with an aggressive course of disease, particularly patients with AML. (biomedcentral.com)
Failure1
- Beyond optimal response is known as warning or failure whereby each indicates treatment continuation, carefully considering or changing according to the patient's conditions. (biomedcentral.com)
Induction1
- In early phase clinical trials for both acute and chronic myeloid leukemias, we have observed the induction of anti-tumor immunity and associated clinical responses following K562/GM-CSF vaccination (see preliminary data). (acgtfoundation.org)
Disorders1
- 2 1 There are a number of hematologic and non-hematologic disorders that are associated with increased BMF ( Table 2 ). (haematologica.org)
Ponatinib1
- Your doctor uses the BCR/ABL percentage (%) to monitor your response to ponatinib. (chemoexperts.com)
Duration1
- Response rate is about 50% and response duration is limited. (biomedcentral.com)
Treatment responses1
- The MLN International Working Group (MLN IWG) was formed to adjudicate diagnoses and treatment responses in the FIGHT-203 study of pemigatinib in MLN with FGFR1 rearrangements. (nature.com)
Patients treated1
- The up-regulation was consistent with the substantial presence of BCR-ABL1 in CML patients treated with TKIs at the molecular response. (biomedcentral.com)
Achieve a complete1
- Most patients achieve a complete hematologic response within four weeks of beginning therapy. (chemoexperts.com)
Analysis1
- Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. (cdc.gov)
Risk1
- Workers' response to risk notification. (cdc.gov)
Rate3
- In patients who receive first-line therapy with TKIs, the rate of decline in BCR-ABL1 transcripts correlates with long-term response. (medscape.com)
- Interestingly, response rate was 44% for patients receiving VPA monotherapy, while none of five patients receiving VPA + ATRA from the start responded. (biomedcentral.com)
- With a median follow-up of 23 months (range = 1-43 months), the overall response rate was 38% for patients receiving azacitidine, 49% for azacitidine plus lenalidomide (P = .14 vs azacitidine), and 27% for azacitidine plus vorinostat (P = .16 vs azacitidine). (ascopost.com)
Therapy1
- Early cytogenetic response or molecular response to second-line and subsequent TKI therapy have also been found to be good predictors of OS and PFS. (medscape.com)
Cells1
- Activation of caspases in response to treatment method with Inhibitors,Modulators,Libraries extracts To achieve insights to the potential mechanisms of apoptosis concerned, caspase 3 seven exercise at the same time as pro tein expression of caspase eight and 9 have been measured for that six most potent extracts in HeLa cells just after sixteen h of remedy. (screeninglibraries.com)
Effects1
- Molecular, cytogenetic, and hematologic effects of ethylene oxide on female hospital workers. (cdc.gov)